195 related articles for article (PubMed ID: 35417939)
21. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
[TBL] [Abstract][Full Text] [Related]
22. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
[TBL] [Abstract][Full Text] [Related]
23. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
25. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
[TBL] [Abstract][Full Text] [Related]
27. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
[TBL] [Abstract][Full Text] [Related]
28. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.
Kameda T; Kataoka K; Kamiunten A; Hidaka M; Miyoshi H; Nakano N; Nosaka K; Yoshimitsu M; Yasunaga JI; Kogure Y; Shide K; Miyahara M; Sakamoto T; Akizuki K; Hidaka T; Kubuki Y; Koya J; Kawano N; Yamashita K; Kawano H; Toyama T; Maeda K; Marutsuka K; Imaizumi Y; Kato K; Sugio T; Tokunaga M; Tashiro Y; Takaori-Kondo A; Miyazaki Y; Akashi K; Ishitsuka K; Matsuoka M; Ohshima K; Watanabe T; Kitanaka A; Utsunomiya A; Ogawa S; Shimoda K
Haematologica; 2023 Aug; 108(8):2178-2191. PubMed ID: 36794502
[TBL] [Abstract][Full Text] [Related]
29. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Blood Adv; 2020 May; 4(10):2180-2191. PubMed ID: 32433748
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma.
Sakamoto Y; Ishida T; Masaki A; Takeshita M; Iwasaki H; Yonekura K; Tashiro Y; Ito A; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Inagaki H
Cancer Sci; 2022 Jan; 113(1):349-361. PubMed ID: 34738707
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Nosaka K; Kusumoto S; Nakano N; Choi I; Yoshimitsu M; Imaizumi Y; Hidaka M; Sasaki H; Makiyama J; Ohtsuka E; Jo T; Ogata M; Ito A; Yonekura K; Tatetsu H; Kato T; Kawakita T; Suehiro Y; Ishitsuka K; Iida S; Matsutani T; Utsunomiya A; Ueda R; Ishida T
Br J Haematol; 2022 Feb; 196(3):629-638. PubMed ID: 34632569
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
34. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Sakamoto Y; Ishida T; Masaki A; Murase T; Yonekura K; Tashiro Y; Tokunaga M; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Inagaki H
Blood; 2018 Aug; 132(7):758-761. PubMed ID: 29930010
[No Abstract] [Full Text] [Related]
35. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
36. Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.
Morichika K; Tomoyose T; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Nishi Y; Nakachi S; Karube KN; Fukushima T; Katoh T; Ohshima K; Masuzaki H
Intern Med; 2016; 55(10):1345-9. PubMed ID: 27181545
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
[No Abstract] [Full Text] [Related]
38. Recent advances in the treatment of adult T-cell leukemia-lymphomas.
Utsunomiya A; Choi I; Chihara D; Seto M
Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789
[TBL] [Abstract][Full Text] [Related]
39. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
[TBL] [Abstract][Full Text] [Related]
40. [Mogamulizumab for the treatment of ATL and PTCL].
Tsukasaki K
Gan To Kagaku Ryoho; 2015 May; 42(5):553-7. PubMed ID: 26054089
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
